Search Result

Results for "

PARPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (177) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (2) Antibiotic (1) Apoptosis (83) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Autophagy (14) Bacterial (2) Bcl-2 Family (11) c-Met/HGFR (1) c-Myc (1) Caspase (19) CDK (6) CFTR (1) Checkpoint Kinase (Chk) (1) Dipeptidyl Peptidase (1) DNA-PK (1) DNA/RNA Synthesis (2) Drug Metabolite (1) Dynamin (1) E3 Ligase Ligand-Linker Conjugates (4) EGFR (2) Endogenous Metabolite (9) Epigenetic Reader Domain (4) Eukaryotic Initiation Factor (eIF) (1) FGFR (2) HDAC (7) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) IAP (1) IGF-1R (1) Influenza Virus (1) IRAK (1) Isotope-Labeled Compounds (2) JNK (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) Microtubule/Tubulin (6) Mitophagy (4) Molecular Glues (2) Nucleoside Antimetabolite/Analog (7) P-glycoprotein (3) p38 MAPK (5) Parasite (5) Phosphatase (3) Phosphodiesterase (PDE) (1) PI3K (2) Poly(ADP-ribose) Glycohydrolase (PARG) (2) PPAR (3) PROTAC Linkers (2) PROTACs (7) Proteasome (1) Reactive Oxygen Species (2) Reverse Transcriptase (1) ROS Kinase (1) Sirtuin (5) Small Interfering RNA (siRNA) (25) STAT (2) Survivin (1) Target Protein Ligand-Linker Conjugates (1) Topoisomerase (2) VEGFR (2)
By Research Areas:	Cancer (217) Cardiovascular Disease (7) Infection (7) Inflammation/Immunology (16) Metabolic Disease (7) Neurological Disease (20)
Click Chemistry:	PROTAC Synthesis (1) Azide (3) Alkynes (2)

284

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-105692

DR2313	PARP	Neurological Disease
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC₅₀s of 0.20 μM and 0.24 μM for *PARP-1* and *PARP-2*, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo .

HY-10162S

Olaparib-d5

AZD2281-d₅; KU0059436-d₅
PARP Autophagy Mitophagy Cancer

Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].
HY-D1107

NCT-TFP

PARP Others

NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1) .

Olaparib-d5 AZD2281-d₅; KU0059436-d₅	PARP Autophagy Mitophagy	Cancer
Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].

NCT-TFP	PARP	Others
NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1) .

HY-10885

A-620223 succinate ABT-472	PARP	Cancer
A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a K_i value of 8 nM and an EC₅₀ value of 3 nM in whole cell assay, making it useful in cancer research .

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-157165

*Tubulin/PARP-IN-1*	Microtubule/Tubulin PARP	Cancer
Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with activity against endometrial cancer. *Tubulin/PARP*-IN-1 inhibits PARP and tubulin with IC₅₀s of 74 nM (PARP1), 109 nM (PARP2), and 1.4 μM (Microtubule/Tubulin), respectively. Tubulin/PARP-IN-1 can induce apoptosis and autophagy and cause cell cycle arrest in the G2/M phase .

HY-132167

Saruparib 3 Publications Verification AZD5305	PARP	Cancer
Saruparib (AZD5305) is a potent, orally active and selective *PARP* inhibitor and trapper with IC₅₀ values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair .

HY-125218

PARP11 inhibitor ITK7 ITK7	PARP	Cancer
PARP11 inhibitor ITK7 (ITK7) is a potent and selective *PARP11* inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC₅₀ value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization . PARP11 inhibitor ITK7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-141486A

*PROTAC PARP/EGFR ligand 1*	PARP EGFR Ligands for Target Protein for PROTAC	Others
PROTAC PARP/EGFR ligand 1 is an active compound that can be used for the synthesis of dual PARP EGFR degraders by proteolytic targeting chimera (PROTAC) technology .

HY-121719

TIQ-A

PARP Cardiovascular Disease Cancer

TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC₅₀ of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .

TIQ-A	PARP	Cardiovascular Disease Cancer
TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC₅₀ of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .

HY-131009

Fluorescein-NAD+	PARP	Others
Fluorescein-NAD+ is an alternative to radiolabeled NAD and a substrate for ADP-ribosylation. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.

HY-120115

PARPi-FL Olaparib-bodipy FL	PARP	Cancer
PARPi-FL is a small molecule and fluorescent inhibitor of *PARP1*. PARPi-FL is a highly selective probe and can be used as an imaging agent to detect glioblastomas in vivo .

HY-160409

TopBP1-IN-1

Others Cancer

TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .

TopBP1-IN-1	Others	Cancer
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with *PARP* inhibitors. TopBP1-IN-1 has antitumor activity .

HY-145584

Nesuparib JPI-547/OCN-201	PARP	Cardiovascular Disease Neurological Disease
Nesuparib is a potent inhibitor of *PARP*. Nesuparib is useful for the research of neuropathic pain, neurodegenerative disease, and cardiovascular disease (extracted from patent WO2016200101A2) .

HY-134354

pNP-ADPr ADP-ribose-pNP	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
pNP-ADPr is a colorimetric substrate that used for the first continuous Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activity assays. pNP-ADPr can be used for the research of poly(ADP-ribose)polymerase (PARP) enzymes .

HY-N7569

Demethoxyfumitremorgin C	Apoptosis Caspase PPAR	Cancer
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to **PARP/ cleavage .**

HY-150696

Antitumor agent-72	Apoptosis Caspase PARP	Cancer
Antitumor agent-72 (compound 6w) is a potent anticancer agent. Antitumor agent-72 has anticancer activity and induces apoptosis through activation of caspase-3 and cleavage of PARP. Antitumor agent-72 can be used for cancer research .

HY-W424851

DPQ hydrochloride 6,7-Dimethoxy-2-(1-piperazinyl)-4-quinazolinamine hydrochloride	PARP	Infection Inflammation/Immunology
DPQ hydrochloride (6, 7-dimethoxy-2 -(1-piperazinyl)-4-quinazolinamine hydrochloride) is a *PARP1* inhibitor, with IC₅₀ value of 40 nM. DPQ hydrochloride has anti-inflammatory and antiviral activity. DPQ hydrochloride is used to study acute lung injury .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available *PARP* inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-144874

AZ3391	PARP	Neurological Disease Cancer
AZ3391 is a potent inhibitor of *PARP. AZ3391 is a quinoxaline derivative. PARP* family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23) .

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-D1188

PARP7-probe-1	PARP	Cancer
PARP7-probe-1 is a chemiluminescent labeled *PARP7* probe. PARP7-probe-1 is a biotinylated probe binding to the PARP7 active site. PARP7-probe-1 can be used for the research of PARP7 function .

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-14478

UPF 1069

1 Publications Verification

PARP Cancer

UPF 1069 is a PARP inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-P2569

Malformin A1	Apoptosis	Cancer
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-148566

OUL232	PARP	Cancer
OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and *PARP15. OUL232 is the most potent PARP10* inhibitor described to date (IC₅₀=7.8 nM), as well as the first *PARP12* inhibitor ever reported .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and TNKS2 inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-102035

PARP-2-IN-1

PARP Cancer

PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC₅₀ of 11.5 nM.

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-132297

PARP1-IN-5

PARP Cancer

PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-146502

PARP10/15-IN-3	PARP Apoptosis	Cancer
PARP10/15-IN-3 (Compound 8a) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.14 µM and 0.40 µM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from apoptosis .

HY-151624

PARP-2-IN-2	PARP Apoptosis	Cancer
PARP-2-IN-2 (compound 27) is a *PARP‑2* inhibitor with an IC₅₀ value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a *PARP1* inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-119653

AZ9482

PARP Cancer

AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-146501

PARP10/15-IN-2	PARP Apoptosis	Cancer
PARP10/15-IN-2 (Compound 8h) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.15 µM and 0.37 µM against PARP10 and PARP15, respectively. PARP10/15-IN-2 is able to enter cells and rescue cells from apoptosis .

HY-155122

PARP-1-IN-13	PARP	Cancer
PARP-1-IN-13 (Compound 19c) is a *PARP-1* inhibitor (IC₅₀: 26 nM). PARP-1-IN-13 inhibits DNA single-strand breakage repair and aggravates DNA double-strand breakage. PARP-1-IN-13 promotes the apoptosis of cancer cells through the mitochondrial apoptosis pathway .

HY-151609

PARP7-IN-12

PARP Cancer

PARP7-IN-12 is a potent PARP7 Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

PARP7-IN-12	PARP	Cancer
PARP7-IN-12 is a potent *PARP7* Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

HY-148709

*ARTD10/PARP10-IN-1*	PARP	Inflammation/Immunology
ARTD10/PARP10-IN-1 (compound 23) is a potent and non-selective *PARP* inhibitor, targeting to mono-ADP-ribosyltransferases *ARTD7/PARP15, ARTD8/PARP14, ARTD10/PARP10* and poly(ADP-ribose) polymerase-1 (ARTD1/PARP1) with IC₅₀s of 1.7 μM, 1.6 μM, 0.8 μM, and 4.4 μM, respectively .

HY-10617

Rucaparib phosphate 30+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617A

Rucaparib 30+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-163081

PARP7-IN-17

PARP Cancer

PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .
HY-162114

PARP1-IN-18

PARP Cancer

PARP1-IN-18 (compound 25) is a potent PARP1 inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6818

5,7,4'-Trimethoxyflavone	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Kaempferia parviflora Wall. ex Baker Plants Disease Research Fields Cancer Zingiberaceae	Apoptosis Caspase PARP Endogenous Metabolite CFTR
5,7,4’-Trimethoxyflavone can be isolated from the medicinal plant Kaempferia parviflora (KP). 5,7,4’-Trimethoxyflavone is a CFTR activator and EC₅₀ is 64 μM. 5,7,4’-Trimethoxyflavone induces apoptosis, increases proteolytic activation of caspase-3, and degradation of ADP-ribose polymerase *(PARP)* protein. 5,7,4’-Trimethoxyflavone has antitumor activity. 5,7,4’-Trimethoxyflavone can be used to prevent skin aging and oxidative stress .

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Classification of Application Fields Other disease Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-N7569

Demethoxyfumitremorgin C	Structural Classification Alkaloids Microorganisms Source classification Marine natural products Other marine organisms Indole Alkaloids	Apoptosis Caspase PPAR
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to **PARP/ cleavage .**

HY-P2569

Malformin A1	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9 .

HY-N10481

Aviculin	Classification of Application Fields Polygonum aviculare L. Polygonaceae Source classification Lignans Phenylpropanoids Plants Disease Research Fields Cancer	Apoptosis Caspase PARP Bcl-2 Family
Aviculin, a lignan glycoside, is a potent anticancer agent. Aviculin reduces metabolic activity on MCF-7 cells below 50%, with an IC₅₀ of 75.47 μM. Aviculin induces breast cancer cell apoptosis through the intrinsic apoptosis pathway. Aviculin increases expression of initiator caspase-9, executioner caspase-7, and poly (ADP-ribose) polymerase (PARP). Aviculin shows an increase in the Bax/Bcl-2 ratio .

HY-N1094

Verminoside	other families Iridoids Classification of Application Fields Anti-aging Terpenoids Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	PARP MDM-2/p53
Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of *PARP-1* and p53 proteins .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-130476

Satratoxin G	Structural Classification Microorganisms Terpenoids Sesquiterpenes Source classification	Caspase Apoptosis
Satratoxin G is a large cyclic mucor toxin. Satratoxin G induces apoptosis by activation of caspase .

HY-N1988

Cucurbitacin IIa Hemslecin A	Triterpenes Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Hemsleya chinensis Cogn. ex Forbes et Hemsl. Disease Research Fields Cancer	Survivin Apoptosis
Cucurbitacin IIa is a triterpene isolated from Hemsleya amalils Diels, induces apoptosis of cancer cells, reduces expression of survivin, reduces phospho-Histone H3 and increases cleaved PARP in cancer cells .

HY-122935

Nigranoic acid	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	HIV Reverse Transcriptase
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .

HY-N6861

Lucidenic acid B	Triterpenes Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Terpenoids Source classification Polyporaceae Plants Endogenous metabolite Disease Research Fields Cancer	Apoptosis
Lucidenic acid B is a natural compound isolated from Ganoderma lucidum, induces apoptosis of cancer cells, and causes the activation of caspase-9 and caspase-3, and cleavage of PARP. Lucidenic acid B does not affect the cell cycle profile, or the number of necrotic cells .

HY-N3584

Paris saponin VII 1 Publications Verification Chonglou Saponin VII	Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of *Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

HY-N3825

ent-Kaurane-3α,16β,17-triol	Structural Classification Terpenoids Source classification Euphorbia stracheyi Boiss. Diterpenoids Euphorbiaceae Plants	Apoptosis
ent-Kaurane-3α,16β,17-triol (Compound 3) is an anticancer agent. ent-Kaurane-3α,16β,17-triol induces apoptosis in HCT116 cells .

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N0674A

Dehydrocorydaline chloride Maximum Cited Publications 22 Publications Verification 13-Methylpalmatine chloride	Infection Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline chloride elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline chloride shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N0674

Dehydrocorydaline Maximum Cited Publications 22 Publications Verification 13-Methylpalmatine	Infection Alkaloids Structural Classification Classification of Application Fields Corydalis yanhusuo W. T. Wang Source classification Plants Isoquinoline Alkaloids Disease Research Fields Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities . Dehydrocorydaline shows strong anti-malarial effects (IC₅₀=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N0674B

Dehydrocorydaline (hydroxyl) 20+ Cited Publications 13-Methylpalmatine (hydroxyl)	Structural Classification Alkaloids Corydalis yanhusuo W. T. Wang Source classification Plants Papaveraceae	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline (13-Methylpalmatine) hydroxyl is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline hydroxyl elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. Dehydrocorydaline hydroxyl shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain.

HY-N4238

Dehydrocorydaline nitrate 20+ Cited Publications 13-Methylpalmatine nitrate	Infection Alkaloids other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields	Bcl-2 Family Caspase PARP p38 MAPK Parasite Autophagy
Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates *PARP* . Dehydrocorydaline nitrate elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities. . Dehydrocorydaline nitrate shows strong anti-malarial effects (IC₅₀ =38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain .

HY-N8572

3',4'-Dimethoxyflavone	Flavonoids other families Flavones Coniogramme japonica (Thunb.) Diels Plants	PARP Reactive Oxygen Species Aryl Hydrocarbon Receptor
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of *PARP* and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .

HY-123033A

Nicotinamide riboside chloride 5+ Cited Publications	Alkaloids Structural Classification Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Pyridine Alkaloids Metabolic Disease Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside Chloride, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033

Nicotinamide riboside	Natural Products Human Gut Microbiota Metabolites Microorganisms Animals Neurological Disease Classification of Application Fields Anti-aging Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033B

Nicotinamide riboside tartrate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside tartrate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

HY-123033C

Nicotinamide riboside malate	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Sirtuin Endogenous Metabolite
Nicotinamide riboside malate, an orally active NAD ⁺ precursor, increases NAD ⁺ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5

Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].
HY-Z0283S

Benzamide-15N

Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-10162S1

Olaparib-d8
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

Cat. No.	Product Name		Classification

HY-150221

DB008		Alkynes
DB008 is potent and selective *PARP16* inhibitor with an IC₅₀ value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130652

Pomalidomide 4'-PEG3-azide		Azide
Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3 is a highly efficient *PARP1*?degrader based on Rucaparib by using the PROTAC approach . Pomalidomide 4'-PEG3-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-W021401

Amino-PEG3-C2-Azido		PROTAC Synthesis Azide
Amino-PEG3-C2-Azido is a PEG-based PROTAC linker can be used in the synthesis of the PARP1 degrader iRucaparib-TP3 (HY-130645) . Amino-PEG3-C2-Azido is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-145749

PARPYnD		Alkynes
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-130654

(S,R,S)-AHPC-C2-PEG4-N3 VH032-C2-PEG4-N3		Azide
(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC₅₀) of 82 nM . (S,R,S)-AHPC-C2-PEG4-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PARPs

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products